Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Naftidrofuryl Hydrogen Oxalate→

Naftidrofuryl Hydrogen Oxalate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
3200-06-4
Molecular formula
C26H35NO7
Molecular weight
473.6 g/mol
Drug class
Peripheral vasodilatorselective 5-HT2 receptor antagonist
Mechanism of action
Selectively blocks vascular and platelet 5-hydroxytryptamine (5-HT2) receptors, reducing serotonin-mediated vasoconstriction and platelet aggregation. It may also improve tissue oxidative metabolism by supporting aerobic energy production.
Indications / reported uses
  • Treatment of intermittent claudication associated with peripheral arterial disease when exercise and other non-pharmacological measures have not provided adequate symptomatic benefit, under the applicable product label and NICE guidance.

Sources: https://www.nice.org.uk/guidance/ta223/chapter/3-The-technologies · https://www.nice.org.uk/guidance/cg147/chapter/recommendations · https://pmc.ncbi.nlm.nih.gov/articles/PMC7075104/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Naftidrofuryl Hydrogen Oxalate Environmental Risk Assessment (ERA) (the Naftidrofuryl Hydrogen Oxalate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.